Pfizer to buy drugs approaching Modevishn exchange for $ 14 billion

US pharmaceutical giant "Pfizer" is in negotiations to acquire a company producing drugs treat cancer, "Mdevishn" in exchange for a deal worth $ 14 billion.

The media, including the newspaper "Venanchal Times" and the British agency "Bloomberg" of America, the announcement of the completion of the transaction may not be released as early as this week.

It produces Mdevishn, based in the state of San Francisco, a drug treatment of prostate "Akestenda" cancer.

The French pharmaceutical company, "Sanofi" had tried to acquire a Mdevishn, while the two companies, "Merck & Co." and "Saghein" also made good offers.

Reuters reported on Sunday that Pfizer has agreed in principle to pay $ 80 a share for Madvishn, a big difference from the offer made by Sanofi-French of $ 52.50 per share, in the April / April last.

Product portfolio Pfizer drug "Aabranis" includes for the treatment of breast cancer and other promising products for the prevention of tumors.

In addition to drug Akestenda which is licensed to sell medical authorities in the United States and is expected to achieve sales of $ 5.7 billion by 2020, Madev_n owns a drug under development for the treatment of breast cancer called "Talazoprip."

Medevishn was founded in 2004, and increased its share price more than doubled during the last six months amid purchase negotiations.

In April / April the past, Pfizer has canceled a planned merger plan with the company "Allergan" after the Irish faced problems due to plans to amend the US tax laws.

The US Treasury Department has announced plans to stop known as the deals "to avoid paying taxes," which means the merger with the American company in the other country imposes a lower tax rate.

It was supposed to become a Pfizer-Allergan deal amounting to $ 160 billion, the largest model of operations "to avoid paying taxes" through the merger of companies with each other.